New Zealand: screening important to improved cancer survival trend
This article was originally published in Clinica
A trend of decreasing cancer death rates-may be partly due to the impact of screening programmes, earlier diagnosis and treatment improvements." So said New Zealand's ministry of health principal advisor for cancer control John Childs. He was commenting on the latest official figures shown in the report, "Cancer patient survival covering the period from 1994-2003", published by the New Zealand Health Information Service (NZHIS).
You may also be interested in...
Reforms to the US 180-day exclusivity incentive included in the Blocking Act that is part of the Lower Health Care Costs Act could cost the US healthcare system approximately $1.7bn, the AAM has warned.
Moderate growth at Bristol-Myers Squibb and Amgen moved the two companies into the top 10 pharma ranks, based on the most recent Scrip 100 rankings, while declining growth at Gilead and Teva moved those drug makers out.